<<Bladerunner, One could just as easily ask why Organon would put a different AMPA upmodulator into the clinic if they're so happy with Org-24448? >>
No, that's incorrect. Everyone wants a backup compound in the clinic. CX717 shows why, but there have been many other programs where the first lead flamed out. Secondly, Org26576 may have a slightly different profile of activity, perhaps it performed better in the forced swim test or some other animal depression model. It doesnt say anything about negative perceptions of Org24448--but Blade is correct, if Organon thought there was a class effect, they wouldnt have doubled their exposure.
'
<< I don't think it's been firmly established yet that Org-26576 is definitely a Cortex developed compound.>>
True. It is governed by the agreement for sure--it probably came from the menu of choices Organon took from Cortex, but I'm not certain of its provenance.
<< As we saw, Servier decided to go ahead with their own non-Cortex compound.>>
You'll be interested to know that Servier recently discontinued (for the second time) that MCI trial with S18986 due to toxicity issues (no, not the CX717 issue)--S18986 is probably dead.
<<All I'm saying is that based on the numerous landmines we've hit over the past year, we should be careful with our assumptions, particularly the rosy type.>>
Who can argue with that? But let's not become overly paranoid, either.
<<if they're doing their job right, the FDA SHOULD want to see additional tox data on Org-24448>>
Could be. But if the FDA was thinking of this as a possible class effect, they've had 8 months since they put the clinical hold on CX717 to take action vis-a-vis Org24448. Instead, the clinical trial program has continued. That by no means guarantees that the FDA couldnt shift course--but Organon has (they aren't brain dead, after all) replicated some of those tox studies with Org24448, so that if the FDA asks, they have the data ready.
NeuroInvestment
News 
Market Data 
Discover 
AI
